Mauna Kea Technologies to Present at the 9th Annual Lazard Healthcare Conference on November 14, 2012
November 08 2012 - 11:45AM
Marketwired
Mauna Kea Technologies (NYSE Euronext: MKEA), leader in the optical
biopsy market and developer of Cellvizio®, the fastest way to see
cancer, today announced that Sacha Loiseau, PhD, Founder and CEO
will present at the 9th Annual Lazard Healthcare Conference taking
place on November 13-14 in New York City. Mr. Loiseau's
presentation is scheduled for Wednesday, November 14, 2012 at 3:30
pm ET.
As previously reported, Mauna Kea Technologies achieved a 91
percent increase in sales during the first nine months of 2012
compared to the same period in 2011. The Cellvizio system now is
available in more than 45 countries worldwide and has received
important regulatory clearances in recent months in Canada, the
Russian Federation and Brazil. The company recently announced the
European launch of the AQ Flex™ 19, the first in a new line of
Cellvizio miniprobes to provide real-time, cellular-level
visualization inside pancreatic cysts during needle-based
procedures. In the United States, the American Medical Association
(AMA) approved the creation of three Class I CPT® codes for
reimbursement of Cellvizio procedures in the upper gastrointestinal
tract and use in pathology. These codes will influence insurance
coverage and reimbursement with Medicare and private US insurance
programs once they go into effect on January 1, 2013. In addition,
more than 140 peer-reviewed publications underscoring the value of
Cellvizio have been published to date.
To access a live webcast of this presentation, visit
http://www.maunakea-corp.com/. A replay will be available for two
weeks at the above-referenced website.
About Mauna Kea Technologies Mauna Kea
Technologies is a global medical device company dedicated to the
advent of optical biopsy. The company researches, develops and
markets innovative tools to visualize and detect cellular
abnormalities during endoscopic procedures. Its flagship product,
Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE)
system, provides physicians and researchers high-resolution
cellular views of tissue inside the body. Large, international,
multicenter clinical trials have demonstrated Cellvizio's ability
to help physicians more accurately detect early forms of disease
and make treatment decisions immediately. Designed to improve
patient outcomes and reduce costs within a hospital, Cellvizio can
be used with almost any endoscope. Cellvizio has 510(k) clearance
from the U.S. Food and Drug Administration and the European CE-Mark
for use in the GI tract, biliary and pancreatic ducts and
lungs.
For more information about Mauna Kea Technologies, visit
www.maunakeatech.com.
United States Lazar Partners Ltd. Erich Sandoval
Tel: +1 917 497 2867 esandoval@lazarpartners.com France and
Europe ALIZE RP Caroline Carmagnol Tel: +33 (0)1 42 68
86 43 / +33 (0)6 64 18 99 59 caroline@alizerp.com Mauna Kea
Technologies Eric Cohen Vice-President Finance Tel: +33 (0) 1
70 08 09 70 investor-vpf@maunakeatech.com NewCap. Investor
Relations and Financial Communication Pierre Laurent / Florent Alba
Tel: +33(0)1 44 71 94 94 maunakea@newcap.fr